

HSE Approved ODMS Drugs and associated ICD-10 codes

Drug	Tumour	HSE Approved Indication	ICD-10 Codes	Date added
AtezolizumAB	Non-small cell cancer (NSCLC)	Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.	C34	01/05/2025
	Non-small cell cancer (NSCLC)	Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.	C34	01/05/2025
	Bladder Cancer	As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy.	C65, C66, C67, C68	01/05/2025
	Bladder Cancer	As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%	C65, C66, C67, C68	01/05/2025
	Non-small cell cancer (NSCLC)	As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC	C34	01/05/2025
	Hepatocellular carcinoma (HCC)	In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.	C22	01/05/2025
	Breast cancer	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease	C50	01/05/2025
	Small cell lung cancer (SCLC)	First-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	C34	01/05/2025
AvelumAB	Bladder Cancer	First-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy	C65, C66, C67, C68	01/05/2025
	Merkel cell carcinoma	Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease	C44	01/05/2025
Axicabtagene ciloleucel (KTE 19) (CAR-T)	Lymphoma - Non-hodgkin's (NHL)	For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy	C83,C85	01/05/2025
BlinatumomAB	Acute lymphoblastic leukaemia (ALL)	As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia	C91	01/05/2025
	Acute lymphoblastic leukaemia (ALL)	As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy	C91	01/05/2025
	Acute lymphoblastic leukaemia (ALL)	As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%	C91	01/05/2025
	Acute lymphoblastic leukaemia (ALL)	Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).	C91	01/05/2025

HSE Approved ODMS Drugs and associated ICD-10 codes

BrentuximAB Vedotin	Systemic anaplastic large cell lymphoma (SALCL)	in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (SALCL)	C84	01/05/2025
	Cutaneous T-Cell lymphoma	The treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy	C84	01/05/2025
	Systemic anaplastic large cell lymphoma (SALCL)	Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (SALCL).	C84	01/05/2025
	Lymphoma - Hodgkin's	The treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option	C81	01/05/2025
	Lymphoma - Hodgkin's	Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT)	C81	01/05/2025
Cabazitaxel	Prostate Cancer	The treatment of patients with hormone-refractory metastatic prostate cancer (mHRPC) previously treated with a docetaxel-containing treatment regimen.	C61	01/05/2025
Carfilzomib	Multiple Myeloma	In combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy	C90	01/05/2025
	Multiple Myeloma	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy	C90	01/05/2025
Cemiplimab	Cutaneous Squamous Cell carcinoma	As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.	C44	01/05/2025
DaratumumAB	Multiple Myeloma	As monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.	C90	01/05/2025
	Multiple Myeloma	In combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy.	C90	01/05/2025
	Amyloidosis	In combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain amyloidosis.	E85	01/05/2025
	Multiple Myeloma	In combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant	C90	01/05/2025
	Multiple Myeloma	In combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	C90	01/05/2025
Daunorubicin (liposomal) and cytarabine	Acute myeloid leukaemia (AML)	For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)	C92	01/05/2025
Decitabine	Acute myeloid leukaemia (AML)	The treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.	C92	01/05/2025
DurvalumAB	Non-small cell cancer (NSCLC)	As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 $\geq 1\%$ on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)	C34	01/05/2025

HSE Approved ODMS Drugs and associated ICD-10 codes

Enfortumab vedotin	Bladder Cancer	As monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 inhibitor (PD-L1).	C65, C66, C67, C68	01/05/2025
Eribulin	Breast cancer	For the treatment of patients with locally advanced or metastatic breast cancer which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.	C50	01/05/2025
GemtuzumAB ozogamicin	Acute myeloid leukaemia (AML)	Indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL)	C92	01/05/2025
InotuzumAB ozogamicin	Acute lymphoblastic leukaemia (ALL)	Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).	C91	01/05/2025
IpilimumAB	Melanoma	Treatment of adults with advanced (unresectable or metastatic) malignant melanoma	C43	01/05/2025
Lutetium oxodotreotide (Lu177)	Neuroendocrine Tumours (gastroenteropancreatic origin)	Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults	C16-20, C25, C26	01/05/2025
Mifamurtide	Osteosarcoma	Mifamurtide can be used in combination with post-operative multi-agent chemotherapy for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults. This treatment is an option to be discussed with the patient (or parent of a child).	C40,C41	01/05/2025
MogamulizumAB	Cutaneous T-Cell lymphoma	As monotherapy for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy	C84	01/05/2025
Nab-paclitaxel	Pancreatic cancer	In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas	C25	01/05/2025
NivolumAB	Melanoma	As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection	C43	01/05/2025
	Bladder Cancer	As monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression $\geq 1\%$, who are at high risk of recurrence after undergoing radical resection of MIUC, providing patients are unsuitable for adjuvant treatment with platinum based chemotherapy.	C65, C66, C67, C68	01/05/2025
	Lymphoma - Hodgkin's	As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.	C81	01/05/2025
	Melanoma	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	C43	01/05/2025
	Renal cell cancer (RCC)	As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults	C64	01/05/2025
	Non-small cell cancer (NSCLC)	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer (NSCLC) after prior chemotherapy in adults.	C34	01/05/2025

HSE Approved ODMS Drugs and associated ICD-10 codes

	Head and neck squamous cell carcinoma (HNSCC)	As monotherapy is indicated for the treatment of squamous cell cancer of the head and neck (HNSCC) in adults progressing on or after platinum-based therapy	C00-C14, C30-C32, C76	01/05/2025
	Oesophageal Cancer	For the adjuvant treatment of oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.	C15,C16	01/05/2025
	Oesophageal Cancer	Nivolumab in combination with fluoropyrimidine and platinumbased combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression $\geq 1\%$.	C15	01/05/2025
	Non-small cell cancer (NSCLC)	In combination with ipilimumab and 2 cycles of platinum-based chemotherapy for first-line treatment of metastatic NSCLC in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	C34	01/05/2025
	Renal cell cancer (RCC)	In combination with ipilimumab for the first-line treatment of adult patients with intermediate-/poor-risk advanced renal cell carcinoma.	C64	01/05/2025
	Mesothelioma	In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.	C45	01/05/2025
	MSI high Colorectal Cancer	In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-HmCRC) after prior fluoropyrimidine-based combination chemotherapy.	C18-20	01/05/2025
	Melanoma	In combination with ipilimumAB for the treatment of advanced (unresectable or metastatic) melanoma in adults.	C43	01/05/2025
	Non-small cell cancer (NSCLC)	In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression $\geq 1\%$.	C34	01/05/2025
Obinutuzumab	Follicular Lymphoma	In combination with chemotherapy, followed by maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma	C82	01/05/2025
	Chronic lymphocytic leukaemia (CLL)	In combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy	C91	01/05/2025
	Follicular Lymphoma	ObinutuzumAB in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximAB or a rituximAB-containing regimen	C82	01/05/2025
PembrolizumAB	Melanoma	As monotherapy for the treatment of adults with unresectable or metastatic melanoma	C43	01/05/2025
	Melanoma	As monotherapy is indicated for the adjuvant treatment of adolescents aged 12 years and older and adults with stage 3 melanoma and lymph node involvement who have undergone complete resection	C43	01/05/2025
	Non-small cell cancer (NSCLC)	As monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a $\geq 50\%$ tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations	C34	01/05/2025
	Lymphoma - Hodgkin's	As monotherapy is indicated for the treatment of paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) following at least two prior therapies when ASCT is not a treatment option.	C81	01/05/2025

HSE Approved ODMS Drugs and associated ICD-10 codes

	Lymphoma - Hodgkin's	As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.	C81	01/05/2025
	Bladder Cancer	As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10	C65, C66, C67, C68	01/05/2025
	Bladder Cancer	As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy	C65, C66, C67, C68	01/05/2025
	Head and neck squamous cell carcinoma (HNSCC)	As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1 .	C00-C14, C30-C32, C76	01/05/2025
	Head and neck squamous cell carcinoma (HNSCC)	Pembrolizumab is indicated, in combination with CARBOplatin and 5- Fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1 .	C00-C14, C30-C32, C76	01/05/2025
	Head and neck squamous cell carcinoma (HNSCC)	Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1 .	C00-C14, C30-C32, C76	01/05/2025
	MSI high Colorectal Cancer	First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.	C18-20	01/05/2025
	Renal cell cancer (RCC)	For the adjuvant treatment of patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.	C64	01/05/2025
	Melanoma	For the treatment of ipilimumAB-refractory patients with unresectable or advanced metastatic melanoma	C43	01/05/2025
	Non-small cell cancer (NSCLC)	In combination with pemetrexed and carboplatin chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.	C34	01/05/2025
	Non-small cell cancer (NSCLC)	In combination with pemetrexed and cisplatin chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.	C34	01/05/2025
	Breast cancer	In combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence.	C50	01/05/2025
	Gastric cancer	In combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment for patients with locally advanced unresectable or metastatic carcinoma of the oesophageal or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 10 .	C15,C16	01/05/2025
PertuzumAB	Breast cancer	In combination with trastuzumAB and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence	C50	01/05/2025

HSE Approved ODMS Drugs and associated ICD-10 codes

	Breast cancer	Is indicated for use in combination with trastuzumAB and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.	C50	01/05/2025
PertuzumAB, trastuzumab and	Breast cancer	Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early	C50	01/05/2025
	Breast cancer	Use in combination with docetaxel for treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for metastatic disease.	C50	01/05/2025
Pixantrone	Lymphoma - Non-hodgkin's (NHL)	Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.	C83, C85	01/05/2025
Polatuzumab vedotin	Lymphoma - Non-hodgkin's (NHL)	In combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.	C83, C85	01/05/2025
	Lymphoma - Non-hodgkin's (NHL)	In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).	C83, C85	01/05/2025
Radium 223	Prostate Cancer	As monotherapy or in combination with LHRH analogues for the treatment of adult patients with castration-resistant metastatic prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available licensed systemic mCRPC treatment	C61	01/05/2025
Sacituzumab govitecan	Breast cancer	As monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.	C50	01/05/2025
SiltuximAB	Multicentric Castleman's disease (MCD)	Sylvant is indicated for the treatment of adult patients with Multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative.	D36, D47	01/05/2025
Tafasitamab	Lymphoma - Non-hodgkin's (NHL)	In combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).	C85	01/05/2025
Teclistamab	Multiple Myeloma	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	C90	01/05/2025
Tisagenlecleucel-T (CTL019) (CAR-T)	Lymphoma - Non-hodgkin's (NHL)	Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy	C83, C85	01/05/2025
	Acute lymphoblastic leukaemia (ALL)	Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse	C91	01/05/2025
Trastuzumab deruxtecan	Breast cancer	Monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.	C50	01/05/2025

HSE Approved ODMS Drugs and associated ICD-10 codes

TrastuzumAB emtansine	Breast cancer	as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy	C50	01/05/2025
	Breast cancer	The treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumAB and taxane, separately or in combination. Patients should have either: <ul style="list-style-type: none"> • Received prior therapy for locally advanced or metastatic disease, or • Developed disease recurrence during or within six months of completing adjuvant therapy. 	C50	01/05/2025